IRS-2, but not IRS-I, can sustain proliferation and rescue UBF stabilization in InR or InR defective signaling of 32D myeloid cells

Cell Cycle

Volumn 8, Issue 19, 2009, Pages 3218-3226

  Wu, Shufang ^a   Zhou, Bo ^a   Xu, Lin ^a   Sun, Hongzhi ^a  

^a NONE

Author keywords

32D myeloid cells; Differentiation; IRS 1; IRS 2; Proliferation; UBF

Indexed keywords

BINDING PROTEIN; CYCLIN D1; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYELOPEROXIDASE; RIBOSOME DNA; UNCLASSIFIED DRUG; UPSTREAM BINDING FACTOR;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GRANULOCYTE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 70349914202     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.19.9759     Document Type: Article

References (32)

1. Valentinis B, Navarro N, Zanocco-Marani T, Edmonds P, McCormick J, Morrione A, et al. Insulin receptor substrate-1, p70S6K and cell size in transformation and differentiation of hemopoietic cells. J Biol Chem 2000; 275:25451-25459 (Pubitemid 30687045)
2. Baserga R, Peruzzi F, Reiss K. The IGF-I receptor in cancer biology. Int J Cancer 2003; 107:873-877
3. Baserga R. The insulin-like growth factor-1 receptor as a target for cancer therapy. Expert Opin Ther Targets 2005; 9:753-768 (Pubitemid 41131677)
4. Ogata N, Chikazu D, Kubota N, Terauchi Y, Tobe T, Azuma Y, et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest 2000; 105:935-943 (Pubitemid 30203066)
5. Akune T, Hoshi K, Kubota Y, Terauchi K, Tobe Y, Azuma T, et al. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol 2002; 159:147-156 (Pubitemid 35191526)
6. Sun H, Baserga R. Deletion of the pleckstrin and phosphotyrosine binding domains of insulin receptor substrate-2 does not impair its ability to regulate cell proliferation in myeloid cells. Endocrinology 2004; 145:5332-5343 (Pubitemid 39551155)
7. Gilliland DG, Tallman MS. Focus on acute leukemias. Cancer Cell 2002; 1:417-420
8. Brown G, Drayson MT, Durham J, Toellner KM, Hughes PJ, Coudhry MA, et al. HL60 cells halted in G1 or S phase differentiate normally. Exp Cell Res 2002; 281:28-38. (Pubitemid 35373780)
9. Ward AC, Smith L, de Koning JP, van Aesch Y, Touw IP. Multiple signals mediate proliferation, differentiation and survival from the granulocyte-colony stimulating factor receptor in myeloid 32D cells. J Biol Chem 1999; 274:14956-14962 (Pubitemid 129518828)
10. Sun H, Tu X, Prisco M, Wu A, Casiburi I, Baserga R. Insulin-like growth factor I receptor signaling and nuclear translocation of insulin receptor substrates 1 and 2. Mol Endocrinol 2003; 17:472-486 (Pubitemid 36315640)
11. Tu X, Batta P, Innocent N, Prisco M, Casaburi I, Belletti B, Baserga R. Nuclear translocation of insulin receptor substrate-1 by oncogenes and IGF-I: Effect on ribosomal RNA synthesis. J Biol Chem 2002; 277:44357-44365 (Pubitemid 36157871)
12. Sun H, Tu X, Baserga R. A mechanism for cell size regulation by the insulin and IGF-1 receptors. Cancer Research 2006; 66:11106-11109
13. Sun H, Tu X, Liu M, Baserga R. Dual Regulation of upstream binding factor 1 levels by IRS-1 and ERKs in IGF-1-receptor signaling. J Cell Physiol 2007; 212:780-786 (Pubitemid 47267547)
14. Baserga R. Is cell size important? Cell Cycle 2007; 6:814-816
15. La Rocca G, Shi B, Badin M, De Angelis T, Sepp- Lorenzino L, Baserga R. Growth inhibition by microRNAs that target the insulin receptor substrate-1. Cell Cycle 2009; 8:2255-2259
16. Baserga R. The insulin-like growth factor-1 receptor as a target for cancer therapy. Expert Opin Ther Targets 2005; 9:753-768 (Pubitemid 41131677)
17. Robert K, Dearth R, Cui XJ, Kim HJ, Hadsell DL, Lee AV. Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle 2007; 6:705-713 (Pubitemid 46535683)
18. Gibson SL, Ma ZF, Shaw LM. Divergent roles for IRS-1 and IRS-2 in breast cancer metastasis. Cell Cycle 2007; 6:631-637 (Pubitemid 46535670)
19. Xiao H, Yin T, Wang XY, Uchida T, Chung J, White MF, Yang YC. Specificity of interleukin-2 receptor chain superfamily cytokines is mediated by insulin receptor substrate-dependent pathway. J Biol Chem 2002; 277:8091-8098 (Pubitemid 34968263)
20. Soon L, Flechner L, Gutkind JS, Wang LH, Baserga R, Pierce JH, Li W. Insulin-like growth factor 1 synergizes with interleukin 4 for hematopietic cell proliferation independent of insulin receptor substrate expression. Mol Cell Biol 1999; 19:3816-3828 (Pubitemid 29193841)
21. Dalmizrak O, Wu A, Chen J, Sun H, Fransiscus E. Utama, Diana Zambelli, et al. Insulin receptor substrate- 1 regulates the transformed phenotype of BT-20 human mammary cancer cells. Cancer Res 2007; 67:2124-2130 (Pubitemid 46424231)
22. Sun H, Baserga R. The role of insulin receptor substrate- 1 in transformation by v-src. J Cell Physiol 2008; 215:725-732 (Pubitemid 351632694)
23. Huang C, Thirone ACP, Huang X, Klip A. Differential contribution of insulin receptor substrate-1 versus 2 to insulin signaling and glucose uptake in L6 myotubes. J Biol Chem 2005; 280:19426-19435 (Pubitemid 41379651)
24. Stefanovsky VY, Pelletier G, Hannan R, Gagnon-Kugler T, Rothblum LI, Moss T. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol Cell 2001; 8:1063-1073 (Pubitemid 34031808)
25. Stefanovsky VY, Pelletier G, Hannan R, Gagnon-Kugler T, Rothblum LI, Moss T. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol Cell 2001; 8:1063-1073 (Pubitemid 34031808)
26. Klippel A, Escobedo MA, Wachowicz MS, Apell G, Brown TW, Giedlin MA, et al. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol Cell Biol 1998; 18:5699-5711 (Pubitemid 28450521)
27. Bader AG, Vogt PK. An essential role for protein synthesis in oncogenic cellular transformation. Oncogene 2004; 23:3145-3150
28. Belinsky MG, Lori CAI Q, Huang M, Mehren M, Godwin AK. The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell Cycle 2008; 7:2949-2955
29. Voit R, Grummt I. Phosphorylation of UBF at serine 388 is required for interaction with RNA polymerase I and activation of rDNA transcription. Proc Natl Acad Sci USA 2001; 98:13631-13636 (Pubitemid 33115949)
30. Comai L, Song Y, Tan C, Bui T. Inhibition of RNA polymerase I transcription in differentiated myeloid leukemia cells by inactivation of selectivity factor-1. Cell Growth Diff 2000; 11:63-70. (Pubitemid 30078667)
31. Drakas R, Tu X, Baserga R. Control of cell size through phosphorylation of upstream binding factor1 by nuclear phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 2004; 101:9272-9276 (Pubitemid 38812865)
32. Wu A, Chen J, Baserga R. The role of insulin receptor substrate-1 in the oncogenicity of simian virus 40 T antigen. Cell Cycle 2008; 7:1999-2002. (Pubitemid 352030345)